The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-13; most recent amendment 2026-01-22.
Status change: Recruiting → Active, Not Recruiting2026-01-22
Status change: Not Yet Recruiting → Recruiting2025-11-25